Novo Nordisk Launches Wegovy at ₹17,345

Wegovy is a once-a-week injection with a monthly dosage cycle, starting with 0.25 mg before rising gradually

- Jessica Jani

Novo Nordisk launched its blockbuster weight loss drug Wegovy (Semaglutide) in India on Tuesday, ahead of a patent expiry next year, which will see generic versions flooding the Indian market.

Wegovy is a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1) indicated for weight management and reduction in risk of major adverse cardiovascular events in India.

The drug will be available in a pen-filled device in five doses—0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and a maintenance dose of 2.4 mg. The first three doses are priced at ₹4,336 for a single dose and ₹17,345 monthly, while the 1.7 mg dose is priced at ₹24,280 per month and the 2.4 mg at ₹26,015 monthly.